NCT lookup

Inclusion Criteria:

All subjects

* Affiliation to a social security scheme, universal medical coverage (CMU) or any equivalent scheme
* Physical state compatible with the carrying out of the investigations according to the judgment of the investigator
* Procedure for obtaining consent

For HFpEF patients:

* Hospitalization in one of the partner hospitals in the last 30 months
* With a diagnosis of symptomatic congestive heart failure (NYHA II to IV)
* With a plasma concentration of BNP ≥ 100 μg / ml or NT-proBNP ≥ 300 μg / ml or having had an administration of a dose of intravenous diuretics during hospitalization for congestive heart failure
* Left ventricular ejection fraction ≥ 50%
* Hospital discharge for at least 2 months

For HFrEF patients:

* Hospitalization in one of the partner hospitals in the last 30 months
* With a diagnosis of symptomatic congestive heart failure (NYHA II to IV)
* Plasma concentration of BNP ≥ 100 μg / ml or NT-proBNP ≥ 300 μg / ml or administered a dose of intravenous diuretics during hospitalization for congestive heart failure
* Hospital discharge for at least 2 months
* Left ventricular ejection fraction ≤ 40%
* Matched age and sex to HFpEF patients (for participants to extensive phenotyping)

For subjects apparently without heart failure :

* Subject without a notable medical history or medical history within the last 5 years
* Normotensive or who may have an essential hypertension of grade 1 (≤159 / 99 mmHg), treated or not
* Can present a dyslipidemia, treated by hygieno-dietetic measures alone
* Sinus heart rate
* Estimated glomerular filtration rate ≥ 60 ml / min (CKD epi)
* Matched age and sex to HFpEF patients (for participants to extensive phenotyping)

Exclusion Criteria:

All subjects

* Pregnancy or breastfeeding
* Participation in another interventional study
* Person placed under the safeguard of justice
* Subject that can not understand the procedures related to the protocol
* Severe obesity (BMI \> 40 Kg / m2)
* For those performing the injected MRI: Patient who has already had a severe allergy to gadolinium MRI contrast agents
* For those performing the injected MRI: MRI usual contraindications: Pace-maker, defibrillator, metallic objects
* Administration of a vaccine dose (including anti-Sars-Cov-2) less than 3 weeks old

For both HFpEF and HFrEF patients:

* History of right ventricular infarction
* History of cardiac transplantation or circulatory assistance
* Major surgery scheduled for less than 6 months, coronary revascularization of less than 3 months
* Pacemaker or any implanted device (or foreign body) not compatible with MRI
* Presence of very severe co-morbidity: end-stage renal failure (GFR \<15ml / min), severe chronic obstructive pulmonary disease (COPD), severe valve disease (including severe aortic stenosis), organ transplantation
* Hypertrophic cardiomyopathy of known genetic cause
* Hereditary amyloidosis with disabling neuropathy
* Amyloidosis under specific treatment
* Other antecedent of known congenital heart disease type, Post-embolic chronic pulmonary heart, Restrictive Cardiopathy, Diagnosed Fabry Disease

For HFpEF patients:

\- History of systolic dysfunction with proven LVEF reduction (≤ 40%)

For subjects apparently without heart failure :

* Medication use other than pure systemic or local estrogen / progestin and progestin contraceptives and paracetamol, at the discretion of the investigator
* Acute pathology within 8 days prior to inclusion
* Cardiac or vascular organic impairment or apparent chronic diseases
* Chronic treatment outside a treatment for high blood pressure
* Having already had ≥3 MRI with injection of gadolinium contrast agents

• Paris, France